Creative Medical Technology (NASDAQ:CELZ – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.16), FiscalAI reports.
Creative Medical Technology Trading Up 2.6%
Shares of CELZ stock opened at $0.62 on Friday. Creative Medical Technology has a 1 year low of $0.59 and a 1 year high of $4.72. The firm’s 50 day moving average is $0.87 and its 200-day moving average is $1.54. The firm has a market capitalization of $4.10 million, a price-to-earnings ratio of -0.31 and a beta of 2.10.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the stock. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. Wall Street Zen upgraded Creative Medical Technology from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Weiss Ratings lowered Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.
Creative Medical Technology Company Profile
Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.
The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.
See Also
- Five stocks we like better than Creative Medical Technology
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
